Perrigo Gets "Wake-Up Call" In FDA Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Perrigo prioritized correcting manufacturing problems that drew an FDA warning, advising the firm to prevent human errors with tighter quality control, according to CEO Joseph Papa
You may also be interested in...
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.
Rolaids Recall Puts Contract Manufacturers In Issa's Crosshairs
Rep. Darrell Issa's questions on what FDA knew about the third-party manufacturer of a product Johnson & Johnson recently recalled reflect the accountability the incoming Oversight and Government Reform Committee chairman will demand from the agency.
Novartis Extends Triaminic Into Brand Name Void Left By J&J Tylenol Recall
Novartis expedites a Triaminic line extension to take advantage of the branded product gap left by the recall of Johnson & Johnson's Children's Tylenol liquid OTCs